Wall Street brokerages expect Horizon Pharma PLC (NASDAQ:HZNP) to announce earnings of $0.50 per share for the current quarter, according to Zacks. Three analysts have made estimates for Horizon Pharma’s earnings, with the lowest EPS estimate coming in at $0.47 and the highest estimate coming in at $0.53. Horizon Pharma posted earnings of $0.26 per share during the same quarter last year, which indicates a positive year over year growth rate of 92.3%. The business is scheduled to issue its next earnings report before the market opens on Wednesday, November 7th.
According to Zacks, analysts expect that Horizon Pharma will report full-year earnings of $1.58 per share for the current financial year, with EPS estimates ranging from $1.50 to $1.64. For the next year, analysts expect that the business will post earnings of $1.86 per share, with EPS estimates ranging from $1.60 to $2.12. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that that provide coverage for Horizon Pharma.
Horizon Pharma (NASDAQ:HZNP) last released its earnings results on Wednesday, August 8th. The biopharmaceutical company reported $0.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.17. Horizon Pharma had a negative net margin of 28.02% and a positive return on equity of 19.05%. The business had revenue of $302.84 million for the quarter, compared to analysts’ expectations of $275.51 million. During the same period last year, the company earned $0.41 earnings per share. The company’s quarterly revenue was up 4.6% on a year-over-year basis.
Shares of HZNP traded up $0.22 during mid-day trading on Friday, hitting $18.27. The company had a trading volume of 1,083,819 shares, compared to its average volume of 1,672,029. The company has a debt-to-equity ratio of 2.19, a quick ratio of 1.63 and a current ratio of 1.70. Horizon Pharma has a 1-year low of $12.55 and a 1-year high of $21.25. The stock has a market capitalization of $3.26 billion, a PE ratio of 15.48, a P/E/G ratio of 1.24 and a beta of 1.40.
In other Horizon Pharma news, EVP Geoffrey M. Curtis sold 9,904 shares of Horizon Pharma stock in a transaction that occurred on Thursday, August 16th. The shares were sold at an average price of $20.63, for a total transaction of $204,319.52. Following the transaction, the executive vice president now directly owns 28,767 shares of the company’s stock, valued at $593,463.21. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 3.90% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. United Services Automobile Association lifted its position in Horizon Pharma by 11.0% during the second quarter. United Services Automobile Association now owns 27,036 shares of the biopharmaceutical company’s stock valued at $448,000 after buying an additional 2,679 shares in the last quarter. SG Americas Securities LLC lifted its position in Horizon Pharma by 25.9% during the second quarter. SG Americas Securities LLC now owns 16,821 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 3,463 shares in the last quarter. Amalgamated Bank lifted its position in Horizon Pharma by 17.2% during the second quarter. Amalgamated Bank now owns 25,270 shares of the biopharmaceutical company’s stock valued at $418,000 after buying an additional 3,711 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its position in Horizon Pharma by 74.4% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,091 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 3,877 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in Horizon Pharma by 2.2% during the second quarter. Rhumbline Advisers now owns 185,346 shares of the biopharmaceutical company’s stock valued at $3,069,000 after buying an additional 3,941 shares in the last quarter. 87.25% of the stock is currently owned by hedge funds and other institutional investors.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
Recommended Story: Conference Calls and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.